- Home
- BNGO vs NRBO Comparison
BNGO vs NRBO Comparison
Compare BNGO & NRBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNGO
- NRBO
- Stock Information
- Founded
- BNGO 2003
- NRBO N/A
- Country
- BNGO United States
- NRBO United States
- Employees
- BNGO N/A
- NRBO N/A
- Industry
- BNGO Biotechnology: Laboratory Analytical Instruments
- NRBO Biotechnology: Pharmaceutical Preparations
- Sector
- BNGO Industrials
- NRBO Health Care
- Exchange
- BNGO Nasdaq
- NRBO Nasdaq
- Market Cap
- BNGO 28.7M
- NRBO 27.9M
- IPO Year
- BNGO 2018
- NRBO N/A
- Fundamental
- Price
- BNGO $0.21
- NRBO $2.35
- Analyst Decision
- BNGO Hold
- NRBO Strong Buy
- Analyst Count
- BNGO 3
- NRBO 1
- Target Price
- BNGO $1.00
- NRBO $10.00
- AVG Volume (30 Days)
- BNGO 3.5M
- NRBO 36.9K
- Earning Date
- BNGO 11-13-2024
- NRBO 11-07-2024
- Dividend Yield
- BNGO N/A
- NRBO N/A
- EPS Growth
- BNGO N/A
- NRBO N/A
- EPS
- BNGO N/A
- NRBO N/A
- Revenue
- BNGO $33,334,000.00
- NRBO N/A
- Revenue This Year
- BNGO N/A
- NRBO N/A
- Revenue Next Year
- BNGO $21.35
- NRBO N/A
- P/E Ratio
- BNGO N/A
- NRBO N/A
- Revenue Growth
- BNGO N/A
- NRBO N/A
- 52 Week Low
- BNGO $0.20
- NRBO $2.08
- 52 Week High
- BNGO $2.27
- NRBO $6.75
- Technical
- Relative Strength Index (RSI)
- BNGO 24.89
- NRBO 39.45
- Support Level
- BNGO $0.27
- NRBO $2.30
- Resistance Level
- BNGO $0.38
- NRBO $2.50
- Average True Range (ATR)
- BNGO 0.02
- NRBO 0.26
- MACD
- BNGO -0.00
- NRBO -0.01
- Stochastic Oscillator
- BNGO 0.00
- NRBO 21.04
About BNGO Bionano Genomics Inc.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in Americas, EMEA and Asia Pacific; majority revenue being generated from Americas. They generate product revenue from sales of its OGM and Ionic Purification systems and consumables, which includes its instruments, and their VIA software.
About NRBO NeuroBo Pharmaceuticals Inc.
NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.